Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0CC8L
|
||||
| Former ID |
DIB003019
|
||||
| Drug Name |
CRILVASTATIN
|
||||
| Synonyms |
Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H23NO3
|
||||
| Canonical SMILES |
CC1CC(CC(C)(C)C1)OC(=O)[C@@H]2CCC(=O)N2
|
||||
| InChI |
1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1
|
||||
| InChIKey |
FXAAOALUHHXBSO-ILDUYXDCSA-N
|
||||
| CAS Number |
CAS 120551-59-9
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | ||||
| Superpathway of cholesterol biosynthesis | |||||
| Mevalonate pathway | |||||
| KEGG Pathway | Terpenoid backbone biosynthesis | ||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| AMPK signaling pathway | |||||
| Bile secretion | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| TSH Signaling Pathway | |||||
| PANTHER Pathway | Cholesterol biosynthesis | ||||
| PathWhiz Pathway | Steroid Biosynthesis | ||||
| WikiPathways | Statin Pathway | ||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Integrated Breast Cancer Pathway | |||||
| SREBP signalling | |||||
| Cholesterol Biosynthesis | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002276) | ||||
| REF 2 | Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.